Business · 23/03/2022Updated: 10/17/2026 · 1 min read
FDA Renews Obstetrics, Reproductive and Urologic Drugs Advisory Committee for 2 Years
Summary
The FDA has renewed the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on March 23, 2024.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →